How long has it been since the last ACR LN guideline updates and why is this significant?

In this educational series, Amanda Mixon, PA-C, President of RhAPP, introduces the latest Lupus Nephritis education based on the updated ACR guidelines. Since the last guidelines in 2012, new therapies like belimumab and voclosporin have revolutionized treatment approaches. The shift from traditional high-dose steroid induction to targeted immune pathway therapies aims to preserve kidney function while reducing medication toxicity. The new guidelines emphasize lower-dose glucocorticoid regimens, triple therapy for Class III & IV Lupus Nephritis, and frequent proteinuria monitoring to optimize patient outcomes. Stay updated with FAQs, podcasts, and medication reviews on the RhAPP website and RhAPP ACE 2.0 Mobile App.